Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.

ABSTRACT:

Objectives

This study evaluated the efficacy and safety of apatinib (an oral small-molecule tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in patients with pretreated metastatic breast cancer in a real-world setting.

Patients and methods

A database of patients with advanced breast cancer who received apatinib between December 2016 and December 2019 in our institution was reviewed, and patients who received apatinib combined with chemotherapy were included. Progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the disease control rate (DCR), and treatment-related toxicity were analyzed.

Results

In total, 52 evaluated patients with metastatic breast cancer previously exposed to anthracyclines or taxane

SUBMITTER: Zhang R 

PROVIDER: S-EPMC10314217 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature